Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
let us all please recall that killing lots of bacteria may not be a good thing. Did someone say gut flora? Recall that ID docs are AGAINST giving antibiotics to COVID patients unless they have to.
Right?
They are against using 1 of 3 big 3 actions unless clearly indicated-
where, oh where is there real action on B UC front? Last PR promises it is coming. Really?
and all that other antiviral research- funny, nothing reported, so how much is really happening?
Not even any grant available for this big antiviral agent?
Sigh.
IP cannot walk and chew gum.
trial failure will doom any IP inhaler of B for C
It has been leaving daily for the last 5 years.
Not.
Q: If B v C fails, then how quickly will all the other B antiviral research move forward?
A: Umm, not too quickly. As in, not at all. No movement. None.
Gosh, gee, it's so extensive and costly and important and moving at warp speed. LOL
Wait for it, wait for it : oh yeah- IP will announce another $15,000 for the Naraynanan lab at GMU.
That' s how important it is right now.
Where is even one little measly grant, with all this hype?
It is bogus until proven otherwise
B works so well against other viruses that there is not a single grant and not a single partner after almost a year of B v C lab studies. All talk, no delivery, so it gets old, very old.
Perhaps you can tell the group what dose of B is needed to achieve the anti inflammatory benefits in hospitalized COVID patients? Or in any COVID patients? Or in a test tube of cells infected with COVID?
And what dose response is expected with B v C inflammation?
I hope that that people can carefully think through these arguments. The hallowed 3 in 1 of B v C? All Infectious disease docs advise against antibiotics in COVID unless there is a proven need. So much for that benefit- nota bene- it may cause MORE harm than benefit. Can you grasp that?
The antiinflamm effect- what's the correct dose for the correct response in a COVID patient? No one has even a clue about this, no lab data even about this with COVID let alone patient data.
The antiviral effect? Those who are hospitalized have very widespread viral illness already. Much damage has already been done and what is left is part inflammatory damage. And we just said how certain we are about B v C inflammatory benefit- we haven't even a CLUE.
Please think critically as you contemplate 3 in 1 exuberance
of course- that is why the share price keeps going down. Leo has made such a compelling case for broader antiviral action.
No grant
No partner
Promises promises
Now is your chance: predict the share price at the time we get news re B v C. Will it hold, or just head for a nickel?
I guess 10-12 cents or so by August and 4-5 cents if the trial fails.
It's the opposite of warp speed.
IP- your slow mo COVID response company
so maybe 6 weeks for the next half Then 29 more days for them all to finish. Then another month for data? So 6-7 + 4 + 4, or so.
Siri tells me that 15 weeks from today is August 11.
Sad and ugly, such a long process.
B v UC still of value...may hold at a nickel
IP- the never ending buying opportunity...LOL
why not buy at 5 cents? No interim data = prurisol, once again.
No B v C interim today = more share price decline.
Get ready for a nickel.
Lots of formulations helpful in a disease with many manifestations. Why does anyone use a steroid enema now, then? Local disease . Avoiding a pill that might have other adverse impacts.
Local only treatment is useful part of the UC armamentarium
Interim B v C data planned per Oct 2 2020 PR.
Remember the planned interim data for B OM? Sure, we got it. And it looked good though the trial final data was not good enough to bring any deal
Remember the planned interim data for P? No, actually. Because we never got it. Announced and then not provided. No final data ever given.
Will B v C data ever even be released?
Let us now turn our attention back to ulcerative colitis, both distal and otherwise.
Please IP: start the oral UC trial already. Walk and chew gum
Also AS- get a move on please-
Heading toward a nickel. Why add now? Why?
No interim B v C = 5 cent value at best
the problem with BOM is that it did not work well enough in the trial to merit a deal, any deal, and the side effects are not critical
IP calculus: share price to approach zero if no interim data out soon. When exactly? Hard to say. But it is easy to predict that all is not well if no prelim data.
Worthless company about to be worth a lot less. No interim data means the trial will fail- more likely than not. Every day that passes now is a problem for investors here, if no data.
Does IP have a lot of potential? Sure. It might even help treat patients with COVID. Steep steep road- wrong trial, wrong place, very tough on us shareholders.
ready for 5 cents? No interim = bad news = the end of the line for B v C trial and the near demise of the company. Can it survive?
"Folks, I could not get a grant of any type even though I tried." The true PR that IP meant to issue goes on to say: " Furthermore, I could not get anyone interested in a partnership. That is how great the Narayanan and Bakovic lab data were. How great is that? Ha. It got us a trial in Russia, so there.
So now I am left to issue silly PRs about some lab data that may or may not pan out. I am doing this to make money for financing as this company struggles to stay alive. You the shareholder are stuck watching ugly share dilution and possible imminent demise.
We might still get lucky. But all I can offer for now is pretend news to make money for others, not you."
No interim data means likely failure- bet on it B v C
safety analysis not the same as planned interim analysis. what could be are to grasp about the difference between apples and oranges? They do appear to be different.
Could anyone miss that?
Ah yes- intentionally, to obscure something that is totally obvious
Unmet needs- IP good at identifying unmet needs- severe mucositis, oral agent for psoriasis, IBD, all viral illness. But finding a drug to meet those needs? So far NOTHING proven.
What a joke. Unmet needs.
Really? Where are the grants or the partners all lined up? and how far will it get if B v C fails?
How pathetic. So much excitement over B that there is NO grant NOTHING and NO partner.
Things are not looking up here folks
Do you believe the words coming out of your CEO's mouth? Not pretending the company misled shareholders. This is changing the subject.
IP/Leo has promised interim analysis for P and B OM and B v C(10/2/2020 PR). If they do not release interim it is BAD news for the company, bad news for B v C.
Very simple.
No B v C interim data=just like P, a loser. Interim data released= like B OM, cautionary, but at least good.
So yes : no interim data is BAD news and interim data may be GOOD news.
This is NOT noise, it is how Leo operates.
completely off base. Could not be simpler. Safety review has NOTHING to do with planned interim analysis. Of course they are different animals.
Of course they are different, apple and orange, and to pretend it is noise is insulting. The pattern for B OM and for P and for B v C is clear- planned interim analysis is NOT the same as the safety stuff.
Agree with you. It is obvious, yet some pretend otherwise. Embarrassing, really.
Public praise to be heaped upon you for your willingness to right a wrong- however small, by looking up the correct PR, which I failed to provide. Rats. AT ANY RATE: The point stands- IP/Leo planned interim for B OM and P and B v C. We shall see if he bothers to let us know
my large # of shares basically worthless now. No point in selling.
This is true of every single shareholder here at 25 cents, except for all of those who have a single digit share price average. What's the point? The company is currently worthless
Some upside possible if B UC ever materializes as an asset. Still possible?
And of course if trial succeeds we are winners.
My guess is failure more likely than not but one never knows. I know as much as those who pretend success is likely- nothing.
Although they pretend to know something at times. Nonsense.
Oct 2 sorry. 10/2/2020 PR states "planned interim analysis"
and interim data? As announced in Dec2 2020 PR? When will that be?
Per prev Leo moves- if no interim data released the drug failed and the company may not survive
three months would mean interim data. Right? Now you agree interim is planned?
It may be planned but up for grabs if Leo will release the data.